VIS 410

Drug Profile

VIS 410

Alternative Names: Influenza virus fusion inhibitor (VIS410) - Visterra; VIS-410

Latest Information Update: 07 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Visterra
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus fusion inhibitors; Influenza virus haemagglutinin glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 30 Jan 2017 Visterra plans a phase IIb trial for Influenza-A virus infections (Combination therapy) (IV) (NCT03040141)
  • 01 Dec 2016 Phase-II clinical trials in Influenza-A virus infections in USA (IV) (NCT02989194)
  • 26 Feb 2016 Pharmacokinetic and adverse events data from a phase I trial in healthy volunteers released by Visterra
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top